Emyria Ltd
ASX:EMD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.023
0.074
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Emyria Ltd
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
